Europe

Jul 29, 2016
Paul Ranson examines how the UK biopharma must now adapt to a changing landscape.
Jul 27, 2016
Leela Barham looks at the EU plans for a European patent, and asks where the UK will fit in after Brexit.
Jul 20, 2016
Not yet, says Reflector. But to judge from the European Parliament's latest foray into the subject, there could be plenty of support for such an approach.
Jul 12, 2016
Pharmaceutical Executive
A look at how Europe’s new accelerated drug approval scheme can move existing review pathways to something better—and take a page from the FDA experience as well.
Jun 09, 2016
Radicals who wield real power at the EMA have gone public with their thinking about the role of regulators in the economic aspects of medicines provision.
Jun 01, 2016
Eleanor Biggs looks at the biggest uncertainties facing the pharma industry if the UK were to leave the EU.
Jun 01, 2016
NHS England head Simon Stevens believes the UK's PPRS needs significantly updating.
May 25, 2016
We desperately need new anti-infective drugs to avoid life threatening infections. Let’s make that happen by punishing companies who don’t invest in R&D for these specific drugs.
May 06, 2016
Pharmaceutical Executive
European pharma is bracing itself for EFPIA’s June deadline requiring the disclosure of transfer-of-value transactions make to HCPs.
Apr 04, 2016
Reflector sees both altruism and self-interest in European thinking on neglected diseases.
native1_300x100
lorem ipsum